Drug Profile
Research programme: mTORC1 modulators - Navitor Pharmaceuticals
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Navitor Pharmaceuticals; X-Chem
- Developer Navitor Pharmaceuticals
- Class Small molecules
- Mechanism of Action MTORC1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Metabolic disorders; Musculoskeletal disorders; Neurodegenerative disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA
- 28 Jul 2018 No recent reports of development identified for research development in Metabolic-disorders in USA